
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer has demonstrated a strong financial performance in the fourth quarter of 2024, surpassing both internal and consensus estimates with higher-than-expected sales from key products, including Comirnaty, Paxlovid, Eliquis, and Ibrance. The company's continued focus on managing its cost base and pursuing business development opportunities, alongside an expected stabilization of COVID-19 revenues, reinforces a positive outlook for 2025. Additionally, with nearly 50% of sales coming from international markets, particularly strong contributions from emerging economies, Pfizer is well-positioned for future growth despite potential fluctuations in COVID-related product demand.
Bears say
Pfizer's stock faces a negative outlook primarily due to disappointing commercial execution on key marketed products such as Padcev, Abrysvo, and Paxlovid, which could dampen investor confidence. Additionally, potential regulatory setbacks and clinical data disappointments concerning line extensions and pipeline assets may hinder future growth prospects. Concerns surrounding U.S. drug pricing reform further contribute to the negative sentiment towards Pfizer, raising skepticism about the company's ability to navigate the evolving pharmaceutical landscape effectively.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares